Roche Has Hopes Of Accelerating Hematology Programs With Surrogate Endpoint
Executive Summary
Roche execs made surrogate endpoints the theme of the company’s recent late-stage pipeline review, highlighting in particular the possible use of minimal residual disease as a surrogate endpoint in the clinical trials for its hematologic agents.
You may also be interested in...
Breast Cancer Protection Plan In Place, Roche Turns Attention To Hematology
With new drugs at hand to protect its Herceptin breast cancer franchise, Roche announced positive data for its rituximab replacement candidate and other steps in its plan to protect top-seller Rituxan/MabThera.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.